Upgrade to SI Premium - Free Trial

Shorting Herbalife (HLF) is 'Absurdly Risky', Says Pivotal Research

May 6, 2016 8:05 AM
Pivotal Research maintained a Buy rating on Herbalife (NYSE: HLF) with a price target of $90. Comments follow the release ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments Litigation Short Sales

Next Articles